New York lawmakers won't pass a 340B drug program protection bill this session, disappointing hospitals and health centers ...

Select hospitals have refused to share data to prove they’re not double-dipping drug discounts, Lilly said. Hospitals, which ...

Eli Lilly moves to deny 340B discounts to hospitals refusing to submit claims data under its documentation policy, escalating ...

Eli Lilly and Company said Monday evening that it will soon end 340B discount pricing for some of the hospitals that have not ...

Three hospitals have sued CVS Health alleging the company redirected $250 million in savings from the 340B program. Mount Sinai Hospital, including St. Luke's-Roosevelt Hospital and Mount Sinai Beth ...

This appeal concerns Maine's effort to use state law to impose additional obligations on drug manufacturers who participate ...

HRSA has extended the deadline for comments on its proposed 340B rebate model pilot program to April 20, 2026. Covered entities have a limited window to submit detailed feedback on how the model would ...

With post-pandemic Medicaid enrollments on the decline and expected to fall further, revenue cycle leaders warn that ...

The past year has seen a great deal of controversy surrounding the 340B Drug Pricing Program, in which drug manufacturers make prescription drugs available to safety net healthcare providers at deeply ...

The Patient Protection and Affordable Care Act is expected to bring significant change to the healthcare industry, including the expansion of the Public Health Service Act Section 340B Program.

Critical decisions are pending before courts and legislators in 2023 that promise to shape the future of the 340B Drug Pricing Program (340B Program), which provides discounts on outpatient drugs for ...

The 340B program was originally designed to assist hospitals that treat under- or uninsured patients in receiving discounted pharmaceutical drugs. Now, the federal subsidy program is getting a second ...